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SUMMARY
Polymyalgia rheumatica (PMR) is a chronic, inflammatory disorder of unknown cause clinically characterized 
by pain and prolonged morning stiffness affecting the shoulders and often the pelvic girdle and neck. Imaging 
has substantially contributed to defining PMR as a disease mainly involving extra-articular structures. This 
review article analyses the role of the different imaging techniques in the diagnosis and follow-up of patients 
with PMR with particular emphasis on the role of ultrasound, PET/CT and MRI.
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n	 INTRODUCTION
Polymyalgia rheumatica (PMR) is a chronic, inflammatory disorder of un-
known cause. It is almost never seen in 
people aged 50 years or younger. Clinical-
ly, the disorder is characterized by pain and 
prolonged morning stiffness affecting the 
shoulders and often the pelvic girdle and 
neck. Symptoms are usually symmetric. 
Inflammatory markers are mostly raised, 
and patients typically experience a swift 
response to glucocorticoids (1). 
n	 IMAGING FINDINGS IN  
POLYMYALGIA RHEUMATICA
In PMR, both joints and periarticular tis-
sues can be involved. Arthritis is typically 
non-erosive and promptly responds to ther-
apy (2), while on imaging the subacromial-
subdeltoid (SAD) and trochanteric bursae 
appear often inflamed (1) (Figure 1). De-
spite the name of polymyalgia (pain in nu-
merous muscles), the muscles have a nor-
mal appearance on imaging (3).
Routine radiographs of inflamed joints do 
not show abnormalities in patients with 
PMR (3). Scintigraphy has gone out of fash-
ion with the advent of imaging techniques 
that provide better spatial resolution, such 
as ultrasonography (US) and magnetic res-
onance imaging (MRI), but has high sensi-
tivity in PMR patients not treated with glu-
cocorticoids (4). 18F-Fluorodeoxyglucose 
positron emission tomography (PET) is not 
routinely used to image patients with PMR, 
but is indicated if large-vessel vasculitis is 
suspected. In addition, PET can also reveal 
inflammatory changes in articular and peri-
articular structures (3). 
Imaging has substantially contributed to 
defining PMR as a disease mainly involv-
ing extra-articular structures. In fact, while 
mild synovitis is a known feature of PMR, 
it was noted that it can only partially ex-
plain the diffuse and severe discomfort of 
the proximal limb extremities experienced 
by PMR patients (5). A pivotal study by 
Salvarani et al. published back in 1997 
clarified that the main source of pain and 
stiffness in PMR with shoulder symptoms 
was SAD bursitis (6). Using MRI, the au-
thors investigated the shoulders of thirteen 
patients with PMR and of nine control pa-
tients with elderly onset rheumatoid arthri-
tis as well as of ten age-matched unaffected 
controls. The main finding of this study 
was that SAD bursitis was present in 100% 
of PMR patients compared with only 22% 
of control patients, while the frequencies of 
joint synovitis and biceps tenosynovitis did 
not significantly differ between case and 
control patients.
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Patients with PMR may also present with 
neck and, less commonly, with lower back 
pain, but the source of spinal pain has long 
not been recognized. Using PET, Block-
mans et al. (7) had observed increased 
FGD accumulation at the level of the spi-
nous processes in about one-half of PMR 
patients, but owing to the relatively low 
spatial resolution of PET the exact ana-
tomical structures involved could not be 
identified. Two subsequent studies spe-
cifically looked at cervical (8) and lumbar 
(9) spine changes in patients with active 
PMR. Using MRI, Salvarani et al. were 
able to identify interspinous bursitis as 
the typical alteration of PMR patients. 
In the first study, twelve untreated PMR 
patients were compared with thirteen 
controls including patients with fibromy-
algia, cervical osteoarthritis, ankylosing 
spondylitis and psoriatic spondylitis (8). 
In all patients with PMR, MRI showed 
the presence of fluid in the cervical inter-
spinous bursae at C5-C7 level consistent 
with bursitis, while bursitis was noted in 
only 46% of control patients. Moderate to 
severe bursitis occurred significantly more 
frequently in PMR (83%) than in control 
(31%) patients. Similarly, MRI evidence 
of lumbar interspinous bursitis was de-
tected in a subsequent study in 90% of 
10 PMR patients, but in only 46% of a 
control group consisting of seven patients 
with spondyloarthropathy, two patients 
with spinal spondylosis and two patients 
with rheumatoid arthritis who had back 
pain (9). On the basis of these findings, it 
was proposed that PMR should be consid-
ered a disorder of extra-articular synovial 
structures (5, 10) and that joint synovitis 
might be secondary to shedding of pro-
inflammatory molecules of extrasynovial 
membranes (10). From a nosological point 
of view, it was thus suggested that PMR 
might share a prevalent extra-articular sy-
novial involvement with other conditions 
such as RS3PE (remitting seronegative 
symmetrical synovitis with pitting edema) 
and probably a subset of elderly onset 
rheumatoid arthritis, with important im-
plications for the classification of arthritis 
in the elderly population (5).
Currently, US has gained a pivotal role in 
the assessment of PMR due to its capacity 
to visualize both joints and periarticular tis-
sues, its low cost and widespread availabil-
ity. Importantly, US in PMR has excellent 
reliability, with very high intra-observer 
(0.96) and inter-observer (0.99) intraclass 
correlation coefficients (11).
The most frequent US abnormalities are 
usually detected at shoulder level and are 
represented by SAD bursitis and long head 
of biceps tendon tenosynovitis (12). Ac-
cording to a recent review, SAD bursitis is 
found in about 70-100% of patients with 
PMR, while the prevalence of long head of 
biceps tendon tenosynovitis hovers around 
45-100% (13). In this context, Rozin et al. 
described the two tram tracks sign, a spe-
cific US sign of active PMR. In some PMR 
patients, the two layers of the deltoid fascia 
and the two leaflets of the subdeltoid bursa, 
when viewed anteriorly with the shoulder 
extended, abducted and internally rotated, 
are seen as parallel hypoechogenic layers. 
This sign has been seen to resolve after 
treatment with glucocorticoids. Just how 
Figure 1 - Distension of the subacromial-deltoid bursa in a patient with PMR. 
In the second figure from top, the main anatomical structures are highlighted 
(the bursa in yellow, the supraspinatus tendon in grey and the bone and bursal 
margins in white).
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prevalent this sign is in PMR is as yet un-
known (14). 
At hip level, extra-articular involvement is 
the most relevant finding with the evidence 
of trochanteric bursitis that is present in a 
significantly higher number of cases with 
PMR than in controls (15). Other findings 
that have been reported are glenohumeral or 
hip joint effusions or tenosynovitis (15-18).
Joint effusion can be also detected in the 
hips, knees, and wrists with prevalence 
rates of 40%, 38%, and 18%, respectively 
(19). Synovitis of hand and wrist are pos-
sible findings, but less helpful in differen-
tiating PMR from other inflammatory con-
ditions such as rheumatoid arthritis (RA). 
Joint involvement at feet level (metatarso-
phalangeal joints) is rare and should sug-
gest another diagnosis.
MRI can also depict periarticular struc-
tures very well. In a study, MRI of the 
shoulders showed bilateral SAD bursitis in 
all PMR patients and biceps tenosynovitis 
in 67%; glenohumeral synovitis was also 
detected in all patients (20). Similarly, at 
hip level using MRI, Cantini et al. dem-
onstrated trochanteric bursitis in 100% 
and hip synovitis in 85% of PMR patients 
(15). US had the same sensitivity as MRI 
for the detection of trochanteric bursitis, 
whereas US findings of hip synovitis were 
present only in 45% of patients. A preva-
lent extra-articular pattern has also been 
demonstrated in the hands of patients with 
PMR using MRI. Cimmino et al. report-
ed tenosynovitis in 67% of 15 PMR pa-
tients versus 30% of unaffected controls; 
extensor tenosynovitis was seen in 53% 
and flexor tenosynovitis in 60% of PMR 
patients, although only the rate of exten-
sor tenosynovitis was significantly higher 
than in controls (21). In contrast, signs of 
synovitis were comparable in PMR pa-
tients and controls. Likewise, in patients 
with florid, PMR-associated RS3PE (re-
mitting seronegative symmetrical synovi-
tis with pitting edema), the most common 
MRI findings are extensor tenosynovitis, 
followed in decreasing order by hand joint 
arthritis and flexor tenosynovitis (22).
A periarticular pattern of PMR has recent-
ly been highlighted in a study by Mackie et 
al. (23). In this study, 22 patients with PMR 
and 16 with RA underwent whole-body, 
multiple-joint, 3T MRI. The authors iden-
tified a pattern of symmetrical extracapsu-
lar inflammation at the level of the greater 
trochanter, acetabulum, ischial tuberosity 
and/or symphysis pubis in 64% of PMR. 
This pattern was associated with higher 
pre-treatment interleukin-6 and C-reactive 
protein levels and a complete response to 
glucocorticoids, as well as with better post-
treatment fatigue and function. However, 
patients presenting with such a pattern 
were more likely to require glucocorticoid 
treatment for >1 year.
PET is also a valuable tool in identifying 
inflammatory changes in PMR as well as in 
disclosing subclinical large vessel vasculi-
tis (Figure 2). In PMR, the increased FDG 
uptake is mainly related to bursitis (peri-
Figure 2 - PET/CT image in a patient with PMR - 
associated vasculitis. The FDG uptake pattern at 
the level of the periarticular structures of the shoul-
ders, hips (bursitis) and humeral head (synovitis) is 
consistent with PMR. In this patient, PET/CT also 
shows an associated large vessel vasculitis (in-
creased vascular FDG uptake at the thoracic aorta, 
subclavian arteries and axillary arteries, score 2 
according to Meller J et al. Eur J Nucl Med Mol 
Imaging, 2003).
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articular accumulation pattern) (24). In 
one of the first papers based on PET pub-
lished by Blockmans et al., high 18F-FDG 
uptake was detected in shoulders in 33/35 
(94%) patients and in hips in 31/35 (89%) 
patients as well as in the spinous process 
of the vertebrae in 51% (7). PET can allow 
assessment of deep bursae, not easily vis-
ible with US, such as ischial tuberosities, 
lumbar spinous processes and greater tro-
chanters. Positive results at this level seems 
to be highly sensitive (85.7%) and specific 
(88.2%) for the diagnosis of PMR, accord-
ing to Yamashita et al. (25).
Rehak et al. recently described various pat-
terns of PET findings in 67 patients who 
fulfilled Healey’s criteria for PMR (26). 
The authors found articular involvement 
in proximal joints in 88.1% of patients 
(86.6% shoulders, 70.1% hips and 46.3% 
sternoclavicular joints). Vascular involve-
ment was seen in 40.3% of patients. Ex-
tra-articular involvement was present in 
ischiogluteal bursae in 52.2% of patients, 
around the symphysis and ventral to pubic 
bones in 7.5% of patients, in spinous inter-
spaces of cervical vertebrae in 19.4% of 
patients and in lumbar vertebrae in 56.7% 
of patients.
Imaging studies are particularly useful in 
securing diagnosis of PMR when the in-
flammatory markers are normal. Cantini et 
al. demonstrated that MRI and US in PMR 
patients with normal or high erythrocyte 
sedimentation rate reveal similar inflam-
matory shoulder lesions (27).
PET is especially helpful in disclosing 
vascular involvement associated with 
PMR, since it can visualize almost all 
arteries including the deeper vessels. 
Blockmans et al. showed that about one-
third of 35 patients with isolated PMR 
had increased vascular FDG uptake (pre-
dominantly in the subclavian arteries) 
(28). However, uptake intensity was less 
marked than in giant cell arteritis, with 
only 2/35 (6%) patients showing intense 
vascular uptake. Moosig et al. (29) de-
scribed increased FDG vascular uptake in 
12 out of 13 PMR patients in the aorta and 
its major branches, but in another study, 
only 2/14 (14%) untreated patients with 
PMR had increased FDG vascular uptake 
(25). Importantly, PMR patients without 
clinical evidence of arteritis but with im-
aging signs of giant cell arteritis do not 
appear prone to developing vascular isch-
emic complications. 
n	 ROLE OF IMAGING IN THE 
CLASSIFICATION CRITERIA OF 
POLYMYALGIA RHEUMATICA
A gold standard diagnostic test for PMR 
is lacking. Moreover, PMR can be mim-
icked by numerous other conditions, many 
of which may also respond in some degree 
to glucocorticoids. Various classification 
criteria have been proposed for diagnos-
ing PMR, including those by Chuang (30), 
Healey (31) and Bird (32). However, none 
of these criteria have been validated or 
been widely accepted. Therefore, new clas-
sification criteria have been developed un-
der the aegis of the American College of 
Rheumatology and of European League 
Against Rheumatism (33). 
In patients aged 50 years or older present-
ing with bilateral shoulder aching and 
raised inflammatory markers, these criteria 
had 68% sensitivity and 78% specificity 
for PMR. US was not mandatory, but when 
ultrasonography findings consistent with 
PMR were included, sensitivity remained 
virtually unchanged at 66%, whereas 
specificity increased to 81%. US findings 
deemed consistent with PMR included at 
least one shoulder with subdeltoid bursitis 
and/or biceps tenosynovitis and/or gleno-
humeral synovitis (either posterior or ax-
illary) and at least one hip with synovitis 
and/or trochanteric bursitis. Macchioni 
et al. recently demonstrated the increased 
specificity of the clinical criteria if inte-
grated with ultrasonography (34). Patients 
with PMR were compared to those with 
other joint inflammatory disorders includ-
ing rheumatoid arthritis (RA). Adding ul-
trasonography, specificity increased from 
81.5% to 91.3% in total cases and from 
79.7% to 89.9% in RA. These findings 
suggest that ultrasonography examination 
is helpful in increasing the specificity of a 
clinical diagnosis of PMR.
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n	 ROLE OF IMAGING IN THE 
DIFFERENTIAL DIAGNOSIS OF 
POLYMYALGIA RHEUMATICA
Current published data suggest a possible 
role for imaging in differentiating PMR 
from other rheumatic conditions that may 
present with a polymyalgic onset. Falsetti 
et al. in 2011 demonstrated an improve-
ment of diagnostic sensitivity for PMR 
when US assessment was used. The authors 
suggested a predictive model of US evalua-
tion to classify PMR patients, including the 
presence of SAD bursitis, low frequency of 
wrist, metacarpophalangeal and metatar-
sophalangeal effusion/synovitis, low fre-
quency of Achilles enthesitis, low frequen-
cy of knee menisci chondrocalcinosis, and 
tendinous calcaneal calcifications, and low 
hypervascularization at power-Doppler US 
analysis in the wrist (13, 18). 
In another study, Falsetti et al. compared 
US findings in patients with PMR versus 
those with RA or spondyloarthropathies 
(SpA) (35). They found that enthesitis was 
more frequent in SpA, while synovitis of 
the elbow, knee, and wrist was significant-
ly more common in patients with RA and 
SpA patients compared with those with 
PMR. At shoulder level, a study that com-
pared PMR with RA and psoriatic arthritis 
(PsA) patients found that bilateral SAD 
bursitis was universal (100%) in patients 
with PMR, whereas only 20% of patients 
of RA patients and no PsA patients had 
such findings (20). In contrast, no signifi-
cant difference was detected in the distri-
bution of biceps tenosynovitis among the 
study groups. Another study that looked 
at shoulder US findings in patients with 
PMR and RA confirmed that SAD bursi-
tis was more specific to PMR (36). In this 
study, bilateral SAD bursitis was revealed 
in 37% of PMR patients, but only in 3% 
of patients with RA, while bilateral biceps 
tenosynovitis was present in 30% of PMR 
patients versus none of the RA controls. A 
semiquantitative scoring system for evalu-
ating periarticular shoulder US inflamma-
tory signs has recently been proposed by 
Suzuki et al. (37). Using a four-point scale 
scoring the hyperemia of the suprascapu-
laris tendon, the authors demonstrated that 
inflammation in PMR was predominantly 
localized to the periarticular tissue com-
pared with elderly-onset RA. The scoring 
showed good intra- and inter-observer reli-
ability.
MRI is also an excellent imaging technique 
for PMR, due to its capacity to visualize in-
flamed tissues at joint and bursae level, and 
has proved useful for the purpose of dif-
ferential diagnosis. In 2001, McGonagle et 
al. published an MRI study comparing the 
anatomical sites of inflammatory changes 
in the shoulders of 14 patients with early 
PMR and 14 with RA using fat suppres-
sion MRI (38). The authors described a 
common involvement of synovial joints 
in PMR and RA and a slightly higher fre-
quency of bursitis in PMR patients. Inter-
estingly, they also described the presence 
of inflammatory changes in the soft tissues, 
defined as extracapsular changes. 
In 2007, the same group published an in-
teresting paper evaluating the relation-
ship between synovial and extracapsular 
inflammation in PMR and early RA us-
ing contrast-enhanced and fat suppression 
MRI (39). The results confirmed a much 
greater degree of gadolinium enhancement 
in the extracapsular tissues in the PMR pa-
tients. A surprising finding was that MRI-
determined erosion and bone edema were 
equally common in both groups, while it 
has been recognized that PMR synovitis is 
usually non-erosive at standard X-ray eval-
uation (22). This finding may be related to 
the capacity of MRI to detect even small 
erosions, which can be found even in nor-
mal subjects (21).
Approximately 16-21% of patients with 
PMR have giant cell arteritis (1). Imaging 
methods can aid in detecting those PMR 
patients that have an associated vasculitis. 
US can be a valuable tool for a correct di-
agnosis of these patients, especially when 
superficial arteries are involved, with a 
sensitivity ranging from 55% to 100% 
and specificity ranging from 78% to 100% 
(40). In large vessel vasculitis, the inflam-
matory infiltrate of the vessel wall results 
in the loss of the normal echostructure of 
the intima-media complex. The major so-
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nographic signs are the thickening of the 
arterial wall with disappearance of the tri-
laminar structure of the intima-media com-
plex, the presence of a perivascular halo, 
and the presence of stenoses or vascular 
dilatations (Figure 3) (41, 42).
PET, too, can be used to detect an under-
lying large-vessel vasculitis as well as to 
depict the pattern of involvement of periar-
ticular structures in PMR. In terms of dif-
ferential diagnosis, PET has been suggest-
ed as useful in differentiating PMR from 
elderly onset RA, with important implica-
tions in terms of prognosis and treatment. 
Yamashita et al. compared FDG accumula-
tion sites at PET between 27 patients with 
PMR and 10 with elderly onset RA. In 
PMR, abnormal accumulation at the ischi-
al tuberosity, vertebral spinous processes, 
and iliopectineal bursa was significantly 
higher compared with RA, while shoul-
der involvement had a similar prevalence 
(25). Similarly, Wakura et al. suggested 
that an abnormal FDG accumulation at the 
entheses of the girdle such as enthesis of 
the pectineus muscle, and enthesis of the 
rectus femoris muscle might assist in dif-
ferentiating PMR from EORA (43). 
n	 ROLE OF IMAGING IN 
ASSESSING TREATMENT 
RESPONSE IN POLYMYALGIA 
RHEUMATICA
There is limited evidence on the role of 
imaging in monitoring patients with PMR. 
In a prospective study containing 53 pa-
tients evaluated clinically, serologically 
and by US before and after (at 4 weeks 
and at 12 weeks) glucocorticoid therapy, 
clinical, laboratory and ultrasonography 
decreased in parallel over time (11). US 
inflammatory findings showed similar or 
better sensitivity to change than clinical 
and laboratory markers of PMR activ-
ity (11). However, in another prospective 
study on 57 newly diagnosed patients with 
PMR, while glucocorticoids significantly 
reduced the frequency and the severity 
of SAD bursitis, long head biceps teno-
synovitis, and glenohumeral synovitis, 
a sizeable 59% of 44 patients in clinical 
remission or in low disease activity had 
persistent inflammatory lesions at follow-
up US (24). No association was found be-
tween the persistence of US inflammatory 
changes and the risk of relapses or recur-
rences, although a positive power-Doppler 
signal at diagnosis was significantly asso-
ciated with the subsequent occurrence of 
relapses or recurrences. Similarly, FDG 
uptake at PET (in the shoulders, hips, and 
spinous processes) was shown to decrease 
following the institution of glucocorti-
coids therapy; however, basal FDG uptake 
did not predict the risk of relapses over 
time (28).
Recently, Palard-Novello et al. suggested 
a role for PET in assessing the efficacy of 
tocilizumab in the treatment of PMR (44). 
Patients enrolled in a multicentric clinical 
trial underwent PET at baseline, after the 
first infusion of tocilizumab (week 2) and 
after the last infusion (week 12). Eighteen 
patients could be evaluated. At week 0, 
high FDG uptake was found at the shoul-
der (89% of patients) and pelvic (94% of 
patients) girdle as well as in the cervical 
spinous processes (56% of patients). After 
the first infusion, SUV max significantly 
decreased and decreased further by week 
12, although in a lesion-based analysis no 
significant decrease was observed in the 
shoulders and cervical spinous processes. 
Further studies are required to fully elu-
cidate the role of imaging in gauging re-
sponse to treatment and monitoring PMR 
patients over time.
Figure 3 - Vasculitis of the axillary arteries in a patient with PMR. Note both in 
the transversal (left) and in the longitudinal view (right) the concentric thicken-
ing of the intima-media complex of the axillary artery at the humeral head level.
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n	 FUTURE PROSPECTS
Imaging appears to increase the specificity 
of a clinical diagnosis of PMR, and to dis-
criminate better between PMR and its mim-
ickers at an early stage. Therefore, imaging 
can conceivably play an important role in 
selecting PMR patients for clinical trials 
with greater accuracy. As suggested by Butt-
gereit et al. (45), imaging including MRI 
could help to identify a fairly homogeneous 
subset of patients with PMR with potential 
value for defining eligibility for early clini-
cal trials of targeted therapies. In addition, 
imaging could also complement clinical 
and laboratory assessments of patients over 
time, including response to therapy.
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